A new pharmacologic treatment for nausea and vomiting of pregnancy

Nurs Womens Health. 2014 Feb-Mar;18(1):73-77. doi: 10.1111/1751-486X.12096.

Abstract

Nausea and vomiting of pregnancy (NVP) affects up to 80 percent of pregnant women. This condition is usually self-limiting, but the symptoms can be distressing and interfere with work, social activities and sleep. Symptoms can often be managed by diet and lifestyle changes, but these interventions may not be successful for everyone. In April 2013, the U.S. Food and Drug Administration approved doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg (Diclegis) as the first medication to specifically treat NVP in more than 30 years. This article reviews the indications, dosage and nursing interventions associated with using doxylamine succinate/pyridoxine to treat NVP.

Keywords: NVP; morning sickness; nausea; pregnancy; vomiting.

Publication types

  • Review

MeSH terms

  • Abnormalities, Drug-Induced / prevention & control
  • Antiemetics / administration & dosage
  • Antiemetics / adverse effects
  • Antiemetics / therapeutic use*
  • Delayed-Action Preparations
  • Dicyclomine / administration & dosage
  • Dicyclomine / adverse effects
  • Dicyclomine / therapeutic use*
  • Doxylamine / administration & dosage
  • Doxylamine / adverse effects
  • Doxylamine / therapeutic use*
  • Drug Administration Schedule
  • Drug Combinations
  • Drug Information Services
  • Female
  • Humans
  • Hyperemesis Gravidarum / drug therapy*
  • Hyperemesis Gravidarum / etiology
  • Morning Sickness / drug therapy*
  • Morning Sickness / etiology
  • Obstetric Nursing / standards
  • Pregnancy
  • Pyridoxine / administration & dosage
  • Pyridoxine / adverse effects
  • Pyridoxine / therapeutic use*
  • Therapeutic Equivalency

Substances

  • Antiemetics
  • Delayed-Action Preparations
  • Drug Combinations
  • dicyclomine, doxylamine, pyridoxine drug combination
  • Dicyclomine
  • Doxylamine
  • Pyridoxine